Cargando…
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?
Pulmonary arterial hypertension (PAH) is a progressive disease that despite advances in therapy is associated with a 7-year survival of approximately 50%. Several risk factors are associated with developing PAH, include methamphetamine use, scleroderma, human immunodeficiency virus, portal hypertens...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074340/ https://www.ncbi.nlm.nih.gov/pubmed/37017914 http://dx.doi.org/10.1007/s40265-023-01862-z |